Pharma Journalist -

Hoth Therapeutics, a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis-also known as eczema-as well as…
Read More...

Merck, known as MSD outside the United States and Canada, announced that it has entered into a definitive agreement to acquire Tilos Therapeutics, a privately held biopharmaceutical…
Read More...

SMi reports: Invitation from conference co-chair released for the 9th Annual Orphan Drugs & Rare Diseases conference, taking place in London this October In October, attendees…
Read More...

CStone Pharmaceuticals announced that the company has entered into a global clinical collaboration with China focus with Bayer HealthCare LLC to evaluate the safety, tolerability,…
Read More...

Biogen announced that it has completed its acquisition of Nightstar Therapeutics, a clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for…
Read More...

Bayer and Arvinas, a biopharmaceutical company creating a new class of therapies to degrade disease-causing proteins, announced an agreement to leverage Arvinas’ novel PROTAC protein…
Read More...

Celgene Corporation and Acceleron Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene’s Biologics License Application (BLA) for luspatercept, an…
Read More...

Vertex Pharmaceuticals Incorporated announced that the company is enhancing its gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy (DMD) and Myotonic…
Read More...

Novartis announced new early stage histology data in kidney transplantation, suggesting that with investigational compound iscalimab (CFZ533) it may be possible to prolong the…
Read More...

Goldfinch Bio, Inc., a biotechnology company focused on developing precision therapies for patients with kidney diseases, announced it has initiated dosing in a Phase 1 clinical trial…
Read More...